- Report
- May 2025
- 106 Pages
Global
From €4169EUR$4,750USD£3,607GBP
- Report
- August 2020
- 250 Pages
Saudi Arabia
From €3159EUR$3,600USD£2,734GBP
- Report
- October 2022
- 177 Pages
From €3028EUR$3,450USD£2,620GBP
- Report
- October 2022
- 174 Pages
North America
From €3028EUR$3,450USD£2,620GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3028EUR$3,450USD£2,620GBP
- Report
- October 2022
- 202 Pages
Europe
From €3028EUR$3,450USD£2,620GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3028EUR$3,450USD£2,620GBP
- Report
- July 2022
- 255 Pages
Global
From €3905EUR$4,450USD£3,379GBP
- Report
- February 2024
- 85 Pages
North America
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 100 Pages
Global
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 80 Pages
Europe
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 176 Pages
Global
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 160 Pages
Africa, Middle East
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 90 Pages
Europe
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 120 Pages
Global
From €4169EUR$4,750USD£3,607GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4169EUR$4,750USD£3,607GBP

Tresiba is a brand of long-acting insulin used to treat diabetes, a chronic endocrine and metabolic disorder. It is a basal insulin, meaning it is taken once or twice daily to provide a steady, low level of insulin throughout the day. It is used to control blood sugar levels in adults and children with type 1 and type 2 diabetes. It is also used to treat diabetic ketoacidosis, a serious complication of diabetes. Tresiba is available in both a pen and a vial form, and is taken in combination with other diabetes medications.
The Tresiba market is a competitive one, with several companies offering similar products. These include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Each company offers a range of long-acting insulin products, including Tresiba, to meet the needs of people with diabetes. Show Less Read more